Dean Destructo
New member
Lasofoxifene and arzoxifene are two newer SERMs that have recently been demonstrated to improve bone mineral density and lower serum cholesterol values compared with older SERMs in smaller clinical trials.
Although SERMs have been available for clinical use for 50 years, recent investigation has focused on large randomized clinical trials for newer indications of older agents or smaller clinical trials of newer agents with improved clinical activity and reduced side effects in specific tissues. In particular, the large, prospective, randomized, controlled, multiyear Study of Tamoxifen and Raloxifene and Raloxifene Use in the Heart clinical trials have recently shown interesting similarities and differences between tamoxifen and raloxifene in estrogen-responsive tissues. Lasofoxifene and arzoxifene are two newer SERMs that have recently been demonstrated to improve bone mineral density and lower serum cholesterol values compared with older SERMs in smaller clinical trials. SARMs are a newer category of drug still being investigated mostly at the basic and preclinical level, with fewer clinical trials available for review. SARMs are currently being investigated mostly for use in prostate cancer at different stages but hold promise for multiple other applications.
<dt style="display: inline; padding: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px; margin-left: 0px !important;">PMID:</dt> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">19412100</dd> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">[PubMed - indexed for MEDLINE] </dd><dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;"></dd><dt style="display: inline; padding: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px; margin-left: 0.5em !important;">PMCID:</dt> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">PMC2860534</dd><dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;"></dd>
Source Credit: Clarke BL1, Khosla S.
Although SERMs have been available for clinical use for 50 years, recent investigation has focused on large randomized clinical trials for newer indications of older agents or smaller clinical trials of newer agents with improved clinical activity and reduced side effects in specific tissues. In particular, the large, prospective, randomized, controlled, multiyear Study of Tamoxifen and Raloxifene and Raloxifene Use in the Heart clinical trials have recently shown interesting similarities and differences between tamoxifen and raloxifene in estrogen-responsive tissues. Lasofoxifene and arzoxifene are two newer SERMs that have recently been demonstrated to improve bone mineral density and lower serum cholesterol values compared with older SERMs in smaller clinical trials. SARMs are a newer category of drug still being investigated mostly at the basic and preclinical level, with fewer clinical trials available for review. SARMs are currently being investigated mostly for use in prostate cancer at different stages but hold promise for multiple other applications.
<dt style="display: inline; padding: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px; margin-left: 0px !important;">PMID:</dt> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">19412100</dd> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">[PubMed - indexed for MEDLINE] </dd><dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;"></dd><dt style="display: inline; padding: 0px; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px; margin-left: 0.5em !important;">PMCID:</dt> <dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;">PMC2860534</dd><dd style="margin: 0px; display: inline; padding: 0px; white-space: nowrap; color: rgb(87, 87, 87); font-family: arial, helvetica, clean, sans-serif; font-size: 11.0045px; line-height: 15.4063px;"></dd>
Source Credit: Clarke BL1, Khosla S.
